Regarding the guidelines, we do not have recommendations regarding the usefulness of preoperative CA125 determination or using tumor markers CA125 in combination or not with HE4 as the sole method in the differential diagnosis of benign/borderline or malignant ovarian tumors in the absence of imaging [65,66,67]. This evidence concerns the gene WFDC2 and ovarian cancer.